At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Guselkumab Dose 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in Participants With Systemic Sclerosis
In Brief
A Phase 2 clinical trial evaluating Guselkumab Dose 1, Guselkumab Dose 2, and 1 other intervention for Scleroderma, Systemic. Completed, enrolled 56 participants across 4 sites.
Detailed Summary
The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScleroderma, Systemic
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionMay 2023
Study CompletionJul 2024
TodayJul 2026
First PostedDec 24, 2020
Enrollment StartFeb 24, 2021
Primary CompletionMay 17, 2023
Study CompletionJul 9, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.5 years ago
Interventions
Guselkumab Dose 1drug
Guselkumab Dose 1 will be administered intravenously.
Guselkumab Dose 2drug
Guselkumab Dose 2 will be administered subcutaneously.
Placebodrug
Placebo will be administered intravenously or subcutaneously.